LU91758I2 - Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) - Google Patents

Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)

Info

Publication number
LU91758I2
LU91758I2 LU91758C LU91758C LU91758I2 LU 91758 I2 LU91758 I2 LU 91758I2 LU 91758 C LU91758 C LU 91758C LU 91758 C LU91758 C LU 91758C LU 91758 I2 LU91758 I2 LU 91758I2
Authority
LU
Luxembourg
Prior art keywords
prolia
denosumab
pharmaceutically acceptable
acceptable derivatives
receptors
Prior art date
Application number
LU91758C
Other languages
English (en)
Other versions
LU91758I9 (fr
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27369779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91758(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of LU91758I2 publication Critical patent/LU91758I2/fr
Publication of LU91758I9 publication Critical patent/LU91758I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LU91758C 1996-12-23 2010-11-24 Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) LU91758I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5997896P 1996-12-23 1996-12-23
US7718197P 1997-03-07 1997-03-07
US6467197P 1997-10-14 1997-10-14
PCT/US1997/023775 WO1998028426A2 (fr) 1996-12-23 1997-12-22 Ligand pour l'activateur des recepteurs du nf-kappab, ligand membre de la superfamille de tnf

Publications (2)

Publication Number Publication Date
LU91758I2 true LU91758I2 (fr) 2011-01-24
LU91758I9 LU91758I9 (fr) 2019-01-02

Family

ID=27369779

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91758C LU91758I2 (fr) 1996-12-23 2010-11-24 Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)

Country Status (13)

Country Link
US (21) US6242213B1 (fr)
EP (5) EP2314695A3 (fr)
JP (7) JP2002509431A (fr)
AT (2) ATE497001T1 (fr)
AU (2) AU713473B2 (fr)
CA (1) CA2274987C (fr)
DE (4) DE69738841D1 (fr)
DK (1) DK0951551T4 (fr)
ES (1) ES2144386T5 (fr)
IL (1) IL130492A (fr)
LU (1) LU91758I2 (fr)
PT (1) PT951551E (fr)
WO (2) WO1998028426A2 (fr)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050060764A1 (en) * 2003-09-17 2005-03-17 Susan Gregory Mouse model for bone metabolism
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US6919434B1 (en) 1995-02-20 2005-07-19 Sankyo Co., Ltd. Monoclonal antibodies that bind OCIF
US20050147611A1 (en) * 1995-12-22 2005-07-07 Amgen Inc. Combination therapy for conditions leading to bone loss
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
WO1999058674A2 (fr) * 1998-05-14 1999-11-18 Immunex Corporation Procede pour inhiber l'activite osteoclastique
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
CA2274803C (fr) * 1996-12-23 2012-05-22 Immunex Corporation Activateur du recepteur de nf-kappab, recepteur membre de la superfamille des recepteurs de tnf
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
JP3523650B2 (ja) 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (fr) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Proteine receptrice nouvelle et son utilisation
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
DE69834719D1 (de) 1997-09-24 2006-07-06 Sankyo Co Methode zur diagnose von abnormalem knochenstoffwechsel
WO1999029865A2 (fr) * 1997-12-12 1999-06-17 The Rockefeller University Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation
US7019119B2 (en) * 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
WO2001060397A1 (fr) 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
US20020106728A1 (en) * 2000-06-20 2002-08-08 Genentech, Inc. NS4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
HRP20010188A2 (en) 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
EP1541587A3 (fr) * 1998-09-15 2007-06-20 Pharmexa A/S Méthode pour diminuer l'activité du ligand de l'ostéoprotégérine
AU779402B2 (en) 1999-04-12 2005-01-20 Genentech Inc. Tumor necrosis factor homologs and nucleic acids encoding the same
US6492124B1 (en) 1999-06-11 2002-12-10 The Rockefeller University Trance activated signal transduction pathways in osteoclasts
US6872806B1 (en) * 1999-06-25 2005-03-29 The Governors Of The University Of Alberta Polypeptide compositions formed using a coiled-coil template and methods of use
EP1194555B1 (fr) 1999-06-28 2012-09-26 Genentech, Inc. Methodes de fabrication de ligands apo-2 a l'aide d'ions metalliques divalents
CA2647796A1 (fr) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Procedes d'inhibition de l'activite des osteoclastes
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US6171860B1 (en) * 1999-11-05 2001-01-09 Isis Pharmaceuticals, Inc. Antisense inhibition of rank expression
AU1920301A (en) * 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
WO2001062932A1 (fr) * 2000-02-23 2001-08-30 Amgen Inc. Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
AU2001266604A1 (en) * 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002009755A2 (fr) 2000-07-27 2002-02-07 Genentech, Inc. Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11
US20040247596A1 (en) * 2000-08-18 2004-12-09 Odgren Paul R. TRANCE regulation of chondrocyte differentiation
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU9303001A (en) * 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
WO2002064782A2 (fr) * 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Polypeptides de liaison de ligand rank -
US20040132971A1 (en) * 2001-02-09 2004-07-08 Haaning Jesper Mortensen Rank ligand-binding polypeptides
US20030013651A1 (en) * 2001-03-22 2003-01-16 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
CA2441538A1 (fr) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation d'osteogenese utilisant des proteines de fusion de ligands rank
WO2002076507A2 (fr) * 2001-03-23 2002-10-03 Genentech, Inc. Utilisations de ligands d'osteoprotegerine (opg) pour la modulation de reponses immunitaires
US20040167072A1 (en) * 2001-05-11 2004-08-26 Aggarwal Bharat B. Inhibitors of receptor activator of NF-kappaB and uses thereof
EP1385872A4 (fr) * 2001-05-11 2004-12-15 Res Dev Foundation Inhibiteurs de recepteur activateur de nf-kappa b et utilisations de ces inhibiteurs
DE02726901T1 (de) * 2001-05-17 2004-07-15 Immunex Corp., Seattle Therapeutische verwendung von rang-antagonisten
US20040213788A1 (en) * 2001-05-18 2004-10-28 Sweet Raymond W. Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
MXPA03011270A (es) * 2001-06-06 2004-03-18 Immunex Corp Uso de antagonistas rank para tratar cancer.
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
JP4509570B2 (ja) 2001-07-03 2010-07-21 ジェネンテック， インコーポレイテッド ヒトｄｒ４抗体及びその使用法
US20030050223A1 (en) * 2001-08-09 2003-03-13 Jonathan Lam Crystal forms and mutants of RANK ligand
EP2348043A1 (fr) 2001-10-02 2011-07-27 Genentech, Inc. Variantes du ligand APO-2 et leurs utilisations
WO2003065972A2 (fr) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methodes de criblage de composes osteogenes
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
US20030100068A1 (en) * 2001-10-12 2003-05-29 Jonathan Lam RANKL mimics and uses thereof
EP1444341A2 (fr) * 2001-10-15 2004-08-11 Barnes-Jewish Hospital Mimetiques de rankl et utilisations de ceux-ci
CA2466054C (fr) 2001-11-13 2012-01-03 Genentech, Inc. Formulations d'apo-2 l/trail
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
US7741285B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7381792B2 (en) * 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
US7399829B2 (en) * 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
EP1560843A4 (fr) * 2002-01-04 2006-09-06 Xencor Inc Nouveaux variants de proteines rankl
WO2003080671A1 (fr) * 2002-03-21 2003-10-02 Komed Co., Ltd. Anticorps monoclonaux anti-rank et compostion pharmaceutique contenant ceux-ci
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
WO2004001009A2 (fr) 2002-06-24 2003-12-31 Genentech, Inc. Variants du ligand apo-2/trail et utilisations de ceux-ci
US20040138162A1 (en) * 2002-08-30 2004-07-15 Roodman G. David Method of resisting osteoclast formation
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
MXPA05006147A (es) * 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
DE602004026157D1 (de) * 2003-01-10 2010-05-06 Protein Crystal Co Ltd Proteinkomplex, verfahren zu dessen herstellung und verwendung davon
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005028633A2 (fr) * 2003-09-17 2005-03-31 Isis Pharmaceuticals, Inc. Modulation de l'expression du rankl
US7252833B2 (en) * 2003-11-18 2007-08-07 Skeletal Kinetics, Llc Calcium phosphate cements comprising an osteoclastogenic agent
JP2007517491A (ja) * 2003-12-29 2007-07-05 株式会社東京大学Ｔｌｏ 免疫調節剤を同定する方法、免疫調節剤、およびこれらの使用法
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2589802A1 (fr) * 2004-12-02 2006-06-08 Domantis Limited Compositions, fusions et conjugues de domaine plad
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
CA2629306A1 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
EP1854458A1 (fr) * 2006-05-08 2007-11-14 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation d'un composé avec activité RANKL
CA2651597C (fr) 2006-05-12 2013-02-05 Keio University Detection d'une maladie inflammatoire et composition destinee a la prevention ou au traitement d'une maladie inflammatoire
US20100105612A1 (en) 2006-10-11 2010-04-29 Oriental Yeast Co., Ltd. Agent containing fused protein of soluble rankl with epitope tag
WO2008044797A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Animal modèle d'ostéopénie
WO2008044379A1 (fr) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Modèle animal de perte osseuse
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008150025A1 (fr) 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. Nouvel agent d'augmentation de la masse osseuse
BRPI0813262A2 (pt) * 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
KR100911852B1 (ko) 2007-11-26 2009-08-11 고려대학교 산학협력단 유세포 분석기를 이용한 신규한 ｒａｎｋ와 ｒａｎｋ리간드의 결합 분석방법
WO2009105934A1 (fr) * 2008-02-27 2009-09-03 上海先导药业有限公司 Anticorps monoclonal anti-rankl humain
AR073072A1 (es) 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
US8657662B2 (en) 2008-09-04 2014-02-25 Patent Investment & Licensing Company Gaming device having variable speed of play
WO2010038610A1 (fr) 2008-09-30 2010-04-08 オリエンタル酵母工業株式会社 Nouvel inducteur de la différenciation et de la prolifération de cellules de cartilage
CN101712964B (zh) * 2008-10-08 2013-05-08 上海科新生物技术股份有限公司 抑制破骨细胞形成的融合蛋白、其制备方法及药物组合物
EP2376120A2 (fr) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Utilisation d'antagonistes dr6 et p75 pour favoriser la survie de cellules du systeme nerveux
CN101514232B (zh) * 2009-03-25 2013-06-19 上海科新生物技术股份有限公司 一种RANKL-Fc融合蛋白及其制备方法和用途
US9079957B2 (en) 2009-04-16 2015-07-14 The University Of Tokyo Diagnosis and treatment of cancer using anti-TMPRSS11E antibody
KR101153393B1 (ko) * 2009-09-21 2012-06-07 고려대학교 산학협력단 점변이 이용한 수용성 재조합 인간 ｒａｎｋ의 효능 향상 및 골 질환 치료용 조성물
EP4450523A3 (fr) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
EP2433644A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Traitement du cancer du sein
EP2434285A1 (fr) 2010-09-22 2012-03-28 IMBA-Institut für Molekulare Biotechnologie GmbH Diagnostic du cancer du sein
ES2562274T3 (es) 2010-10-06 2016-03-03 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Procedimiento para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de mama
WO2012133914A1 (fr) 2011-03-31 2012-10-04 オリエンタル酵母工業株式会社 Potentialisateur d'immunité anticancéreuse contenant un antagoniste de rankl
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
FR2980711A1 (fr) * 2011-10-03 2013-04-05 Centre Nat Rech Scient Modulation du systeme immunitaire et des cellules stromales via rank
WO2013067639A1 (fr) 2011-11-07 2013-05-16 UNIVERSITé LAVAL Utilisation d'antagonistes de rank/rankl pour le traitement de troubles neuromusculaires, de myopathies génétiques et/ou de myopathies non génétiques et/ou pour la régulation de l'inactivité, des maladies et du vieillissement du muscle squelettique et cardiaque
EP2650682A1 (fr) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Esters asymétriques d'acides gras utiles en tant que lubrifiants
EP3467124A1 (fr) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Procédé pour le diagnostic, le pronostic et le traitement des métastases du cancer du poumon
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2888122A1 (fr) 2012-10-12 2014-04-17 Inbiomotion S.L. Procede pour le diagnostic, le pronostic et le traitement d'une metastase du cancer de la prostate au moyen de c-maf
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20160032400A1 (en) 2013-03-15 2016-02-04 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
US20160032399A1 (en) 2013-03-15 2016-02-04 Inbiomotion S.L. Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
EP3030249B1 (fr) 2013-08-07 2019-12-25 Rigshospitalet, Copenhagen University Hospital Anticorps, composés et dérivés associés destinés à être utilisés dans le traitement de l'infertilité masculine
WO2015030701A1 (fr) * 2013-08-24 2015-03-05 R-Pharm Overseas, Inc. Anticorps entièrement humains contre le rankl humain
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
EP3712166A1 (fr) 2013-09-05 2020-09-23 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
EP3524698A1 (fr) 2013-10-09 2019-08-14 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Procédé pour le pronostic et le traitement de métastases cancéreuses
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
ES2939940T3 (es) 2014-03-28 2023-04-28 Univ Duke Tratamiento del cáncer de mama utilizando moduladores selectivos de los receptores de estrógenos
WO2015175861A1 (fr) 2014-05-16 2015-11-19 Amgen Inc. Dosage pour la détection de populations de cellules th1 et th2
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
CN104829725A (zh) * 2015-01-21 2015-08-12 武汉友芝友生物制药有限公司 一种双特异性抗体cd133×cd3的构建及应用
MX384605B (es) 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.
CN107750254B (zh) 2015-05-18 2021-08-20 伊莱利利公司 抗Dkk-1-抗RANKL双特异性抗体化合物
WO2016186071A1 (fr) * 2015-05-20 2016-11-24 国立大学法人大阪大学 Oligopeptide ayant une activité d'inhibition de la sécrétion de cytokine pro-inflammatoire
CA3009350A1 (fr) * 2016-01-05 2017-07-13 The Trustees Of Columbia University In The City Of New York Compositions et procedes de regulation de l'activite de l'inhibiteur de la proteine de liaison a l'adn de type 2 (id2)
WO2017123642A1 (fr) * 2016-01-12 2017-07-20 The Trustees Of The University Of Pennsylvania Méthodes et utilisations du récepteur associé à l'ostéoclaste (oscar) pour la prévention et le traitement de l'arthrose
CN108601833B (zh) * 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
MX2018010851A (es) 2016-03-08 2019-02-07 Janssen Biotech Inc Anticuerpos de gitr, métodos, y usos.
CA3025264A1 (fr) 2016-05-25 2017-11-30 Inbiomotion S.L. Traitement therapeutique du cancer du sein sur la base de l'etat c-maf
EP3484499A4 (fr) 2016-07-14 2020-05-13 Scholar Rock, Inc. Anticorps anti-tgfb, méthodes et utilisations
US10913799B2 (en) 2016-10-28 2021-02-09 Eli Lilly And Company Anti-RANKL antibodies and uses thereof
EP3565542B1 (fr) 2017-01-05 2024-04-10 Radius Pharmaceuticals, Inc. Formes polymorphes de rad1901-2hcl
AU2018235928B2 (en) 2017-03-14 2023-09-21 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CA3082728A1 (fr) 2017-11-22 2019-05-31 Inbiomotion S.L. Traitement therapeutique du cancer du sein sur la base de c-maf
US12325737B2 (en) 2018-03-26 2025-06-10 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
US11499928B2 (en) * 2018-08-24 2022-11-15 University Of Wyoming Methods and systems for isochoric measurements using differential scanning calorimetry
EP3860653A1 (fr) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et systèmes de contrôle des propriétés agonistes de domaines variables d'un anticorps par la lumière
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
US12441745B2 (en) 2019-02-12 2025-10-14 Radius Pharmaceuticals, Inc. Processes and compounds
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
EP4045515A4 (fr) 2019-10-18 2023-10-18 The Regents Of The University Of Michigan Systèmes de capteurs pour biomatériaux
WO2021149012A1 (fr) 2020-01-24 2021-07-29 Radius Health, Inc. Méthodes de stimulation de la croissance osseuse faisant intervenir l'abaloparatide et le denosumab
CN111793135A (zh) * 2020-05-11 2020-10-20 廊坊天光生物技术有限公司 一种用于检测血清中rankl含量的抗体对及其用途
WO2021247892A1 (fr) 2020-06-04 2021-12-09 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
US20240043501A1 (en) 2020-10-15 2024-02-08 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023179791A1 (fr) * 2022-03-24 2023-09-28 Angitia Biomedicines Limited Traitement de troubles musculo-squelettiques
EP4507779A1 (fr) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Procédés de commande de la destruction de cellules tumorales par la lumière
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
JP2026516670A (ja) 2023-04-20 2026-05-26 アムジエン・インコーポレーテツド 相対的な不対グリカン含有量を決定する方法
AU2024325342A1 (en) 2023-08-14 2026-02-26 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2026090253A1 (fr) 2024-10-23 2026-04-30 Amgen Inc. Procédés de détermination de la teneur en appariement de glycanes

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4710457A (en) * 1983-06-29 1987-12-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibody for human hematopoietic glycoproteins and method
US4710473A (en) * 1983-08-10 1987-12-01 Amgen, Inc. DNA plasmids
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
WO1986000922A1 (fr) 1984-07-30 1986-02-13 The Salk Institute For Biological Studies Vecteurs retroviraux de transfert genetique
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
JP2598801B2 (ja) * 1986-07-18 1997-04-09 ザ ユニバーシティー オブ メルボルン 悪性‐ＰＴＨｒＰの液性過カルシウム血症において活性なタンパク
US5846534A (en) * 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1990014363A1 (fr) 1989-05-19 1990-11-29 Amgen Inc. Inhibiteur de metalloproteinase
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
WO1992009697A1 (fr) * 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. UTILISATION EN OSTEOPATHIE D'UNE PROTEINE MORPHOGENETIQUE D'ORIGINE OSSEUSE ASSOCIEE DE MANIERE SYNERGIQUE AVEC DU BETA DE FACTEUR DE CROISSANCE DE TRANSFORMATION (β-FCT).
US6121002A (en) * 1990-12-26 2000-09-19 The Rowett Research Institute Method to detect bone and other connective tissue disorders in humans and animals
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2068389A1 (fr) 1991-05-13 1992-11-14 Masahiko Sato Methode d'inhibition de la resorption osseuse
MX9204303A (es) * 1991-07-23 1993-11-01 Rhone Poulenc Rorer Int Factor regulador del crecimiento de osteoclasto.
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
DK0897983T3 (da) * 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2118119C (fr) 1992-04-30 2001-07-31 Robert C. Thompson Methodes de traitement des affections mediees par le facteur de necrose tumorale et l'interleukine-1
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5578569A (en) * 1993-03-12 1996-11-26 Tam; Cherk S. Method of increasing bone growth
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JPH09502614A (ja) * 1993-09-14 1997-03-18 メルク エンド カンパニー インコーポレーテッド 新規ヒト蛋白質チロシンホスファターゼをコードするｃＤＮＡ
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
EP0727211A1 (fr) 1995-02-10 1996-08-21 Smithkline Beecham Corporation Emploi de composés spécifiques src SH2 dans le traitement de maladies de résorption osseuse
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996028546A1 (fr) 1995-03-15 1996-09-19 Human Genome Sciences, Inc. Recepteur humain du facteur de necrose tumorale
US20030166097A1 (en) * 1995-03-15 2003-09-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US7094564B1 (en) * 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
AU6090896A (en) 1995-06-07 1997-01-15 Osteosa Inc. Osteoclast growth regulatory factor
WO1997000317A1 (fr) 1995-06-07 1997-01-03 Osteosa Inc. Facteur regulateur de la croissance d'osteoclastes
NZ311335A (en) 1995-06-07 1998-05-27 Immunex Corp Cd40l muteins and their use as ligands
CA2225378C (fr) * 1995-06-29 2012-04-17 Immunex Corporation Cytokine inductrice d'apoptose
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
JPH0997808A (ja) 1995-09-29 1997-04-08 Mitsumi Electric Co Ltd ダイボンディング装置
JPH09151434A (ja) 1995-11-24 1997-06-10 Tootetsu:Kk 角形蛇籠の変形防止枠及びその蛇籠の設置方法
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6613544B1 (en) * 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
NZ330926A (en) 1996-01-11 1999-11-29 Immunex Corp Expression augmenting sequence elements (ease) for eukaryotic expression systems
JPH09217897A (ja) 1996-02-14 1997-08-19 Hitachi Ltd Ｓｆ６貯蔵供給装置、その貯蔵方法及び供給方法
JPH09224803A (ja) 1996-02-21 1997-09-02 Nakajima Cafe Honsha:Kk 蓋付きコーヒーカップ
US5766223A (en) 1996-03-21 1998-06-16 Johnson; Deborah M. Child's teething device
US5710013A (en) 1996-04-19 1998-01-20 Tularik Inc. Tumor necrosis factor receptor associated factor 6 (TRAF6)
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
WO1998028423A2 (fr) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions et procedes d'utilisation des facteurs inhibant les osteoclastes
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
WO1999058674A2 (fr) * 1998-05-14 1999-11-18 Immunex Corporation Procede pour inhiber l'activite osteoclastique
JP3523650B2 (ja) 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (fr) * 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Proteine receptrice nouvelle et son utilisation
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
WO1999029865A2 (fr) 1997-12-12 1999-06-17 The Rockefeller University Proteine appartenant a la superfamille des tnf, acides nucleiques la codant et ses methodes d'utilisation
US7063960B2 (en) * 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
US7019119B2 (en) * 1997-12-12 2006-03-28 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) * 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US6252180B1 (en) * 1999-08-09 2001-06-26 Lucent Technologies Inc. Electromagnetic interference cover for a conduit and an electronic equipment chassis employing the same
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
KR20010085996A (ko) 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2001062932A1 (fr) 2000-02-23 2001-08-30 Amgen Inc. Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2003243139B2 (en) * 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7157993B2 (en) 2003-09-30 2007-01-02 Rockwell Scientific Licensing, Llc 1:N MEM switch module

Also Published As

Publication number Publication date
JP2010241823A (ja) 2010-10-28
CA2274987A1 (fr) 1998-07-02
JP2008133302A (ja) 2008-06-12
JP2002509431A (ja) 2002-03-26
EP0951551B1 (fr) 2008-07-16
US20120034690A1 (en) 2012-02-09
DE951551T1 (de) 2000-09-14
ES2144386T9 (es) 2013-02-18
US6479635B1 (en) 2002-11-12
US7744886B2 (en) 2010-06-29
WO1998028424A2 (fr) 1998-07-02
US20050003391A1 (en) 2005-01-06
AU713471B2 (en) 1999-12-02
US20110086033A1 (en) 2011-04-14
JP4242913B2 (ja) 2009-03-25
DE122010000048I1 (de) 2011-05-05
US20110200990A1 (en) 2011-08-18
US6528482B1 (en) 2003-03-04
JP5096527B2 (ja) 2012-12-12
ES2144386T5 (es) 2012-12-07
AU5718498A (en) 1998-07-17
IL130492A (en) 2007-09-20
US6740522B2 (en) 2004-05-25
WO1998028424A3 (fr) 1998-09-11
PT951551E (pt) 2008-10-28
AU713471C (en) 2002-04-18
EP2314695A3 (fr) 2011-12-21
US8153775B2 (en) 2012-04-10
US6537763B2 (en) 2003-03-25
ATE401404T1 (de) 2008-08-15
US8715683B2 (en) 2014-05-06
US8569456B2 (en) 2013-10-29
EP0951551B9 (fr) 2012-12-26
US20020086827A1 (en) 2002-07-04
JP2002509430A (ja) 2002-03-26
US6649164B2 (en) 2003-11-18
US8377690B2 (en) 2013-02-19
US20090017033A1 (en) 2009-01-15
AU713473B2 (en) 1999-12-02
US6017729A (en) 2000-01-25
DK0951551T3 (da) 2008-09-01
US6242213B1 (en) 2001-06-05
US20140235832A1 (en) 2014-08-21
US7411050B2 (en) 2008-08-12
EP2371962A3 (fr) 2011-12-21
ES2144386T1 (es) 2000-06-16
US8333963B2 (en) 2012-12-18
ATE497001T1 (de) 2011-02-15
US20130203682A1 (en) 2013-08-08
DE69740107D1 (de) 2011-03-10
US6419929B1 (en) 2002-07-16
JP2007014339A (ja) 2007-01-25
EP0951551B2 (fr) 2012-08-08
US20140186887A1 (en) 2014-07-03
LU91758I9 (fr) 2019-01-02
US20020081720A1 (en) 2002-06-27
AU5618098A (en) 1998-07-17
EP0946725A2 (fr) 1999-10-06
US7262274B2 (en) 2007-08-28
JP4138013B2 (ja) 2008-08-20
JP4203105B2 (ja) 2008-12-24
DK0951551T4 (da) 2012-09-10
EP0946725B1 (fr) 2011-01-26
WO1998028426A2 (fr) 1998-07-02
JP2008113656A (ja) 2008-05-22
CA2274987C (fr) 2012-01-24
ES2144386T3 (es) 2009-01-16
IL130492A0 (en) 2000-06-01
US7932375B2 (en) 2011-04-26
US20030175840A1 (en) 2003-09-18
US20120178912A1 (en) 2012-07-12
US6838262B1 (en) 2005-01-04
US20020086826A1 (en) 2002-07-04
EP0951551A2 (fr) 1999-10-27
DE69738841D1 (de) 2008-08-28
EP2371962A2 (fr) 2011-10-05
JP2009051862A (ja) 2009-03-12
US20020169117A1 (en) 2002-11-14
US20080009014A1 (en) 2008-01-10
JP4054354B2 (ja) 2008-02-27
EP2003203A1 (fr) 2008-12-17
EP2314695A2 (fr) 2011-04-27
US6562948B2 (en) 2003-05-13

Similar Documents

Publication Publication Date Title
LU91758I9 (fr)
US5789416B1 (en) N6 mono heterocyclic substituted adenosine derivatives
DK0817847T4 (da) IL-17-receptor
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
BG103251A (bg) Оксадиазоли, методи за получаването им и приложението им като лекарствени средства
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
ATE233561T1 (de) Imidazolverbindungen
FI972945A7 (fi) Antigeenien antamiseen soveltuvia koostumuksia
BG101132A (en) Pyridoanilated thienyl and furanyl oxazolidinons
IS4565A (is) 2-methýl-thíenó-bensódíasepín, samsetning til inntöku
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
EE9500064A (et) Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
FI961628A7 (fi) Indolijohdannaisia NMDA-antagonisteina
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
FI970448L (fi) N-substituoituja 3-atsobisyklo(3.2.0)heptaanijohdannaisia,jotka ovat käyttökelpoisia neuroleptisina aineina
FI972988L (fi) Menetelmiä ja farmaseuttisia koostumuksia, joissa käytetään desmetyyliselegiliiniä
FI972306L (fi) Substituoituja 2-aryylikarbonyylioksimetyyli-1,2,5-tiadiatsolidin -3- oni-1,1-dioksidi-johdannaisia ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BG100248A (bg) Инхибитори на скваленсинтетаза
PL331882A1 (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofurane amines and 2-amino cyclohepta[b]benzofuranes
ITBZ950006V0 (it) Guarnitura per mobili.
DE3873278D1 (de) Aryl-substituierte thiophen-3-ole, ihre derivate und analoge als lipoxygenase-inhibitoren.
IT246279Y1 (it) Guarnitura per mobili
ATE217619T1 (de) Endothelin-rezeptor-antagonisten
EE200100062A (et) Uued 2,3,3a,4,9,9a-heksahüdro-8-hydroxy-1H-bens(f)indoolid, meetodid nende valmistamiseks ja nende kasutamine ravimitena